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Background. Chlamydia trachomatis (CT), Mycoplasma genitalium (MG), and Trichomonas vaginalis (TV)
are sexually transmitted infections (STIs) associated with nongonococcal urethritis (NGU). We assessed their pre-
dictors and persistence after treatment.
Methods. We analyzed data from an NGU treatment trial among symptomatic heterosexual men aged 16–45
years from STI clinics. Nucleic acid amplification tests detected CT, MG, and TV at baseline and at 1 and 4 weeks
after therapy. Associations between variables and STI detection were investigated.
Results. Among 293 participants, 44% had CT, 31% had MG, and 13% had TV at baseline. In multivariate
analysis, CT infection was associated with young age and STI contact. Young age was also associated with MG,
and having ≥1 new partner was negatively associated with TV. We detected persistent CT in 12% and MG in 44%
of participants at 4 weeks after therapy, which were associated with signs and symptoms of NGU. Persistent CT
was detected in 23% of participants after azithromycin treatment vs 5% after doxycycline treatment (P = .011);
persistent MG was detected in 68% of participants after doxycycline vs 33% after azithromycin (P = .001). All but
1 TV infection cleared after tinidazole.
Conclusions. Persistent CT and MG after treatment of NGU are common, and were associated with clinical
findings and drug regimen.
Nongonococcal urethritis (NGU) is a frequent diagno-
sis worldwide among adolescent and adult men pre-
senting with urethral discharge or dysuria. There are
no recent estimates of the prevalence of NGU in the
United States; however, data from the 1970s indicate
that 19%–78% of urethritis cases among men in
sexually transmitted infection (STI) clinics and 85% of
urethritis cases on college campuses in the United
States were due to NGU [1, 2]. Chlamydia trachomatis
(CT), Mycoplasma genitalium (MG), and Trichomonas
vaginalis (TV) are the most recognized pathogens con-
tributing to NGU. However, recent studies have dem-
onstrated the contribution of Ureaplasma urealyticum,
herpes simplex virus, and adenovirus to the etiology of
NGU, owing in part to advancements in nucleic acid
amplification tests (NAATs) for detection [3–5].
Empiric therapy is directed primarily at chlamydial in-
fection, yet the clinical manifestations of these patho-
gens are usually indistinguishable and may require
different treatment considerations. Persistent NGU
can occur in a significant proportion of men after
treatment; whether this is due to a slow resolution of
the primary inflammatory response or due to persis-
tent pathogens causing infection is uncertain.
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Treatment recommendations for NGU include azithromy-
cin or doxycycline therapy [6]. A randomized controlled trial
conducted by Schwebke et al [7] found that microbiological
cure differed between CT and MG, with CT having the
highest clearance rate (94.8%) after doxycycline therapy, and
MG having the highest clearance rate (66.7%) after treatment
with azithromycin. This finding raises concern about the dif-
ferent response rates of each pathogen to recommended
therapy and their contribution to persistent NGU. Although a
test-of-cure for NGU (ie, repeat testing at 3–4 weeks after
therapy) is not recommended unless symptoms persist or re-
infection is suspected, the proportion of cases with persistent
infection after treatment should be further delineated.
We conducted an analysis of the data collected by Schwebke
et al [7] to ascertain characteristics associated with CT, MG,
and TV infection at baseline and persistence after therapy in
symptomatic heterosexual men with NGU. In the absence of
point-of-care tests for these organisms in men, recognition of
factors that predict specific infections at baseline could direct
optimal therapy and management of sexual partners. We also
assessed factors associated with microbiological persistence of
CT or MG after standard treatment with azithromycin or dox-
ycycline, and their correlation with persistent NGU.
METHODS
Study Design and Intervention
The multicenter, randomized controlled trial was conducted
from November 2006 to April 2009. Symptomatic heterosexu-
al men aged 16–45 years with NGU were recruited from 4 STI
clinics (Birmingham, Alabama; New Orleans, Louisiana;
Durham, North Carolina; and Baltimore, Maryland). The
master protocol was approved by the University of Alabama at
Birmingham Institutional Review Board (IRB) for Human
Subjects and by IRBs serving each study site.
The primary study objectives, eligibility criteria, enrollment,
and follow-up procedures were previously described [7]. Par-
ticipants were randomized to 1 of 4 arms with standard treat-
ment regimens of azithromycin or doxycycline, with or
without tinidazole [7], and asked to return to the clinics for 2
follow-up visits at 1 week (visit 2) and 3–4 weeks (visit 3) after
completion of therapy. Participants were counseled regarding
sexual abstinence or condom use during the study and were
instructed to refer their sexual partners to the clinic as con-
tacts to NGU.
At enrollment and each follow-up visit, urethral Gram
stains were conducted using standard clinic procedures to
quantify ≥5 polymorphonuclear neutrophils (PMNs) per 3–5
oil immersion high-power fields (HPFs), with 3 of the 4
clinics also quantifying 5–15 PMNs per HPF or >15 PMNs
per HPF. A urine specimen was obtained for detection of
prevalent CT, MG, and TV infections. CT testing was
performed according to the manufacturer’s instructions using
a licensed transcription-mediated amplification (TMA) assay
(APTIMA COMBO 2, Gen-Probe Inc). TV polymerase chain
reaction (PCR) testing was performed centrally at the Univer-
sity of Alabama at Birmingham using specific primers TV3
and TV7 for PCR amplification as previously described [5].
Detection of MG was performed centrally at Louisiana State
University using a TMA-hybridization protection MG analyte
specific reagent assay (Gen-Probe Inc).
Definitions
NGU was defined as new-onset urethral discharge or dysuria
accompanied by a urethral smear with ≥5 PMNs per HPF and
without evidence of Neisseria gonorrhoeae infection deter-
mined by the TMA assay. Persistent NGU was defined as con-
tinued clinical signs and/or symptoms of NGU after
treatment. Microbiological persistence of CT, MG, or TV was
defined as a positive TMA test for these pathogens during the
last evaluable follow-up among participants who were positive
at baseline, irrespective of clinical findings.
In our study, clinical failures after treatment were defined
similar to previous clinical trials [8], based on persistent
symptoms and ≥5 PMNs per HPF on the urethral smear or
persistent urethral discharge on exam at visit 2, and based on
≥5 PMNs per HPF on urethral smear or persistent urethral
discharge regardless of symptoms at visit 3. Clinical failures
received standard treatment for persistent NGU and were dis-
continued from further study follow-up.
Data Analysis
Associations between demographic (age, marital status), be-
havioral (age at first sexual encounter, number of sexual part-
ners in the past 3 months, new partner in the past 30 days,
number of oral or vaginal sexual encounters in the past 30
days, days since last sexual encounter, condom use during last
encounter, urination after sex), and clinical variables (reason
for clinic visit, symptoms, duration of symptoms, physical
exam findings, circumcision status, and urethral Gram stain
results) with presence of organisms or no detectable pathogens
at baseline were initially investigated with χ2 tests. Factors that
were significantly associated at the 0.10 level were entered into
a multivariate logistic model and those whose significance
level remained at <0.10 were retained. Adjusted prevalence
odds ratios (AORs) were estimated with 95% confidence inter-
vals (CIs) to determine independent associations with CT,
MG, and TV infections or having none of these pathogens at
baseline. Associations between clinical outcomes at visits 2
and 3 and microbiological detection of prevalent STIs were
examined with χ2 tests. The associations between variables
and persistent infection based on the last evaluable test result
for each participant after treatment were examined using
exact χ2 or Mantel-Haenszel tests. Only participants with the
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organism detected at baseline and who returned for at least 1
of the follow-up visits were included in these analyses. Statisti-
cal significance was assessed at the 0.05 level.
RESULTS
Three hundred five male participants were enrolled in the
study, and we included 293 with symptomatic NGU after ex-
cluding 12 who did not meet eligibility criteria (4 had gonor-
rhea, 3 had NGU in the past 30 days, 3 were asymptomatic,
and 2 were excluded for other exclusion criteria). The majority
(98%) of participants were African-American, with a median
age of 24 years (range, 17–45). Among those enrolled, 245
(84%) returned for visit 2 (median of 1 week after treatment).
Of the 260 patients not treated as clinical failures at visit 2,
169 (65%) returned for visit 3 (median of 4 weeks from
treatment).
Persistence of STIs Detected by NAATs After Treatment
At the baseline visit, 44.0% (129/293) of our male participants
had CT infection, 31% (90/232) had MG, 13% (39/293) had
TV, and 28% (82/292) had none of the 3 pathogens detected.
Among men identified with CT at baseline who were treated
with either azithromycin or doxycycline, 17% (18/109) had a
positive CT result at visit 2 after treatment and 12% (9/73) at
visit 3. Among 12 men with CT at visit 2 who returned at visit
3, 5 still had persistent CT (Figure 1). Three of the CT infec-
tions at visit 3 were noted in men who were negative at visit 2,
possibly due to reinfection or relapse. Among men with MG
at baseline treated with either azithromycin or doxycycline,
47% (37/78) had a positive result at visit 2, and 44% (24/54) at
visit 3 (Figure 2). Among the 37 men with MG at visit 2 who
returned at visit 3, 20 had persistent MG. For TV, only 14%
(2/14) of men with baseline infection had persistence after
treatment with tinidazole at visit 2, 1 of whom cleared at visit
3 and the other did not return for follow-up.
Associations Between Clinical Outcomes and Microbiological
Data
Following any treatment regimen, 13% (33/245) of the male
participants who were reassessed at visit 2 met the criteria for
clinical failure. However, 55% of these men with clinical
failure had none of the 3 pathogens detected upon retesting at
visit 2; prevalent CT infection was detected in 9%, MG in
33%, and TV in 12% (Figure 3). At visit 3, 47% (80/169) of
the men were identified with clinical failure, of which 10%
Figure 1. Distribution of Chlamydia trachomatis (CT) test results after treatment (visits 2 and 3) for men with positive results at baseline. aThree of
the 6 participants who missed visit 3 were excluded from further study follow-up because of clinical failure at visit 2. bNineteen of the 32 participants
who missed visit 3 were excluded from further study follow-up owing to clinical failure at visit 2.
Figure 2. Distribution of Mycoplasma genitalium (MG) test results after treatment (visits 2 and 3) for men with positive results at baseline. aEleven
of the 16 participants who missed visit 3 were excluded from further study follow-up because of clinical failure at visit 2. bFour of the 11 participants
who missed visit 3 were excluded from further study follow-up owing to clinical failure at visit 2.
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had prevalent CT, 25% had MG, 10% had TV (Figure 3), and
56% had no detectable pathogens. CT was associated with
clinical failure at visit 3 (P = .048), whereas MG was strongly
correlated with clinical failure at both visit 2 (P = .003) and
visit 3 (P < .001).
Predictors of Infection at Baseline in Univariate Analysis
Increasing age was negatively associated with the risk of CT or
MG infection. Conversely, there was a positive association of
increasing age with having none of the 3 pathogens at baseline
and TV infection, but the latter was not statistically significant
(Table 1). Among behavioral factors, reported sex in exchange
for drugs/money or with a prostitute was negatively associated
with CT and positively associated with having none of the 3
pathogens detected at baseline. Reporting ≥1 new sexual
partner in the past 30 days was associated with a reduced risk
of having trichomoniasis compared to no new partners, while
≥2 sexual partners in the past 3 months was negatively associ-
ated with having no pathogens at baseline. Among reasons for
the clinic visit, reported sexual contact with an STI was
strongly associated with CT infection (Table 1). Having >15
PMNs per HPF vs 5–15 PMNs per HPF on urethral Gram
stain was also associated with an increased risk of CT infec-
tion. Other variables including marital status, age at first
sexual encounter, days since last sexual encounter, number of
oral or vaginal sex in the past 30 days, condom use during last
encounter, urination after sex, type or duration of urethral
symptoms, and circumcision status were not significantly asso-
ciated with CT, MG, or TV infections.
Predictors of Infection at Baseline by Multivariate Analysis
After adjusting for other variables in the model, every 5-year
increase in age was significantly associated with a reduction in
the risk of CT (AOR = 0.74, 95% CI, .60–.91) (Table 2). Age
was the only variable retained in the multivariate model for
MG, and every 5-year age increase was also associated with a
20% reduction in the risk of MG. Conversely, every 5-year in-
crease in age remained positively associated with having no
pathogens at baseline (AOR = 1.27, 95% CI, 1.04–1.55).
Regarding behavioral factors, men who had a reported
contact with an STI had a nearly 4-fold increased risk of CT
infection (AOR = 3.92, 95% CI, 1.93–7.98) compared to those
without a reported contact. Men who reported at least 1 new
sexual partner in the past 30 days had a significant reduction
in the risk of TV infection (AOR = 0.20, 95% CI, .06–.66)
compared to those who reported no new sexual partners. A
significant negative association remained between having ≥2
sexual partners in the last 3 months and having no pathogens
at baseline.
When urethral Gram stain results from 3 of the sites that
quantified ≥5 PMNs per HPF were added to the multivariate
model, the AOR was 2.01 (95% CI, 1.09–3.72) for >15 PMNs
per HPF for CT and 2.31 (95% CI, 1.05, 5.09) for >15 PMNs
per HPF for TV compared with 5–15 PMNs per HPF. Con-
versely, having >15 PMNs per HPF on urethral Gram stain
was associated with a reduced likelihood of having no patho-
gen (AOR = 0.39, 95% CI, .19–.78) compared with 5–15
PMNs per HPF.
Factors Associated With Persistent CT or MG Detection
at Follow-up
There were no apparent associations between persistent CT or
MG and risk factors for possible reinfection including report-
ed sex since the last visit or lack of condom use. However,
among men with CT infection at baseline, there was a higher
proportion of persistent CT detected by NAATs in those who
had a visible discharge on follow-up examination compared to
those without a visible discharge (30% vs 10%, P = .028). Men
with >15 PMNs per HPF on urethral Gram stain also had a
higher proportion of persistent CT compared to men with a
Figure 3. Microbiological detection of prevalent Chlamydia trachomatis (CT), Mycoplasma genitalium (MG), and Trichomonas vaginalis (TV) in
participants identified with clinical failure or clinical cure at visit 2 (V2) and visit 3 (V3) after treatment. Abbreviation: NAAT, nucleic acid amplification test.
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Table 1. Univariate Analysis of Baseline Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis Infections According to Demographic, Behavioral, and Clinical
Characteristics in Symptomatic Men With Nongonococcal Urethritis
No.
a
Chlamydia trachomatis Mycoplasma genitalium Trichomonas vaginalis No Pathogen
Baseline Variable No.(Row %) OR (95% CI) No. (Row %) OR (95% CI) No. (Row %) OR (95% CI) No. (Row %) OR (95% CI)
Demographics
Age, mean (SD)
With specified STI … 24.9 (5.8) 0.72 (.60–.87)* 25.2 (5.9) 0.80 (.66–.98)* 28.1 (6.0) 1.20 (.95–1.52) 28.6 (7.8) 1.36 (1.13–1.63)*
Without specified STI … 27.7 (7.2) 27.1 (7.0) 26.3 (6.8) 25.7 (6.6)
Sexual partners
No. in past 3 mo
<2 80 29 (36) 1 22 (28) 1 9 (11) 1 31 (39) 1
≥2 211 99 (47) 1.55 (.91–2.64) 68 (32) 1.26 (.71–2.23) 29 (14) 1.26 (.57–2.79) 51 (24) 0.51 (.29–.88)*
New partner in past 30 d
0 12 2 (17) 1 3 (25) 1 5 (42) 1 5 (42) 1
≥1 279 126 (45) 4.12 (.89–19.13) 87 (31) 1.37 (.36–5.17) 33 (12) 0.19 (.06–.63)* 77 (28) 0.54 (.17–1.74)
Ever had sex in exchange for drugs/money or with prostitute
No 264 123 (47) 1 85 (32) 1 32 (12) 1 68 (26) 1
Yes 28 5 (18) 0.25 (.09–.68)* 5 (18) 0.46 (.17–1.24) 7 (25) 2.42 (.95–6.14) 14 (50) 2.87 (1.3–6.32)*
Sexual encounter
No. of vaginal sex encounters in past 30 d
≤4 146 66 (45) 1 43 (29) 1 21 (14) 1 42 (29) 1
>4 144 62 (43) 0.92 (.58–1.46) 46 (32) 1.14 (.69–1.87) 17 (12) 0.80 (.40–1.58) 40 (28) 0.96 (.58–1.6)
Condom use during last encounter
No 180 73 (41) 1 50 (28) 1 25 (14) 1 56 (31) 1
Yes 112 55 (49) 1.41 (.88–2.27) 40 (36) 1.46 (.88–2.43) 14 (13) 0.89 (.44–1.79) 26 (23) 0.68 (.39–1.16)
Reason for visit (not mutually exclusive)
Symptoms
Yes 220 90 (41) 0.59 (.34–1.00)* 69 (31) 1.09 (.61–1.95) 32 (15) 1.58 (.67–3.75) 63 (29) 1.18 (.64–2.17)
No 72 39 (54) 1 21 (30) 1 7 (10) 1 18 (25) 1
Contact with an STI
Yes 49 34 (69) 3.53 (1.83–6.83)* 12 (24) 0.68 (.34–1.38) 6 (12) 0.89 (.35–2.25) 10 (20) 0.62 (.29–1.3)
No 243 95 (39) 1 78 (32) 1 33 (14) 1 71 (29) 1
Symptoms (not mutually exclusive)
Drip or discharge
Yes 179 82 (46) 1.21 (.75–1.94) 59 (33) 1.30 (.78–2.18) 23 (13) 0.90 (.45–1.79) 44 (25) 0.64 (.38–1.08)






















Chlamydia trachomatis Mycoplasma genitalium Trichomonas vaginalis No Pathogen
Baseline Variable No.(Row %) OR (95% CI) No. (Row %) OR (95% CI) No. (Row %) OR (95% CI) No. (Row %) OR (95% CI)
Burning on urination
Yes 131 57 (44) 0.96 (.61–1.53) 40 (31) 0.98 (.59–1.61) 22 (17) 1.72 (.87–3.40) 31 (24) 0.67 (.4–1.13)
No 162 72 (44) 1 50 (31) 1 17 (10) 1 51 (32) 1
Physical exam findings
Discharge amount
None 24 9 (38) 1 8 (33) 1 2 (8) 1 8 (33) 1
Scant 141 52 (37) 0.97 (.40–2.38)b 45 (32) 0.95 (.38–2.38) 18 (13) 1.61 (.35–7.43) 45 (32) 0.95 (.38–2.38)
Moderate 117 63 (54) 1.94 (.79–4.80)b 33 (28) 0.79 (.31–2.01) 16 (14) 1.74 (.37–8.13) 18 (24) 0.63 (.24–1.63)
Large 11 5 (45) 1.39 (.33–5.90)b 4 (36) 1.14 (.26–5.09) 3 (27) 4.13 (.58–29.39) 1 (9) 0.2 (.02–1.85)
Circumcised
No 53 24 (45) 1 12 (23) 1 8 (15) 1 16 (30) 1
Yes 240 105 (44) 0.94 (.52–1.71) 78 (33) 1.65 (.82–3.32) 31 (13) 0.83 (.36–1.94) 66 (28) 0.88 (.46–1.69)
Urethral Gram stainc
5–15 PMNs/HPF 176 64 (36) 1 51 (29) 1 18 (10) 1 63 (35) 1
>15 PMNs/HPF 80 43 (54) 2.03 (1.19–3.48)* 28 (35) 1.31 (.75–2.30) 15 (19) 2.03 (.96–4.26) 14 (18) 0.39 (.2–.74)*
Abbreviations: CI, confidence interval; OR, odds ratio; PMNs/ HPF, polymorphonuclear leukocytes per high-power field; STI, sexually transmitted infection.
a One participant did not have results for Mycoplasma genitalium testing.
b The overall test for discharge amount was significant for C. trachomatis. The OR based on the 2 largest groups was significant with OR = 2.00 (95% CI, 1.21–3.29) for moderate discharge with scant discharge as the
reference category.














lower number of PMNs per HPF (36% vs 21%, P = .001). A
higher proportion of men treated with azithromycin had per-
sistent CT compared to those treated with doxycycline (23%
vs 5%, respectively; P = .011).
Among men with MG infection at baseline, there was a
higher proportion of persistent MG detected in participants
who reported symptoms of discharge (81% vs 38%, P = .001)
or burning on urination (76% vs 43%, P = .016) at follow-up
compared to those without these symptoms. Similar to CT,
the presence of urethral discharge (P < .001), ≥5 PMNs per
HPF on the urethral Gram stain at follow-up (P = .001), and
the initial treatment regimen were also associated with persis-
tent MG. However, a higher proportion of men with MG at
baseline who were treated with doxycycline had persistent MG
compared to those treated with azithromycin (68% vs 33%,
respectively; P = .001).
DISCUSSION
Overall, we detected persistent CT in 12% and MG in 44% by
NAATs at 4 weeks after therapy. Persistent CT and MG at 4
weeks after therapy were both associated with signs of clinical
failure. Persistent CT or MG were proportionally higher in
men with a urethral discharge on examination or high
number of PMNs per HPF on urethral Gram stain at follow-
up compared to men without a discharge or <5 PMNs per
HPF. However, the proportion of persistent CT or MG dif-
fered based on the initial therapy, with the highest proportion
of persistent CT detected among men treated with azithromy-
cin and persistent MG among men treated with doxycycline.
CT infection at baseline among symptomatic men with
NGU was independently associated with young age and re-
ported contact to an STI. We found that young age was a pre-
dictor of MG infection at baseline, similar to other
investigators [5, 9], while having at least 1 new sexual partner
in the past 2 weeks was the only factor associated with a
reduced likelihood of TV infection. Young age has been iden-
tified as a predictor of CT and MG infections in women
[10–12], so our findings are expected given the likelihood of
age matching among sexual partners and higher rates of
partner change in the young population [13]. In comparison,
TV infection has been associated with older age in both men
[14, 15] and women [16]. We found that increasing age was
associated with an increased likelihood of having none of the
3 pathogens or TV identified at baseline; however, the latter
was not statistically significant, likely owing to the small
number of TV infections in our study.
The decreased odds of TV infection among men who re-
ported at least 1 new sexual partner in the past 30 days was
surprising, given that there were no other associations with
Table 2. Multivariate Analysis of Characteristics Associated With Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vag-
inalis, and Absence of Pathogen at Baseline in Symptomatic Men With Nongonococcal Urethritis
Baseline Variable
Chlamydia trachomatis
(n = 290), AOR (95% CI)
Mycoplasma genitalium
(n = 291), AOR (95% CI)
Trichomonas vaginalis
(n = 291), AOR (95% CI)
No Pathogen (n = 289),
AOR (95% CI)
Age
Per 5 y 0.74 (.60–.91)* 0.80 (.66–.98)* … 1.27 (1.04–1.55)*
Partners in last 3 mo
≥2 vs 0–1 1.81 (1.00–3.30) … … 0.52 (.29–.92)*
New partners in last 30 d
≥1 vs 0 4.42 (.86–22.74) … 0.20 (.06–.66)* …
Ever had sex for drugs/money
or with prostitute
Yes vs no 0.38 (.13–1.10) … 2.39 (.92–6.22) 2.29 (.97–5.42)
Visit for contact with an STI
Yes vs no 3.92 (1.93–7.98)* … …
Discharge amounta
Scant vs none 0.87 (.33–2.30) … … …
Moderate vs none 2.00 (.75–5.33) … … …
Large vs none 1.09 (.23–5.17) … … …
Reported drip or discharge
Yes vs no … … … 0.62 (.36–1.07)
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; STI, sexually transmitted infection.
a The overall test for discharge amount was significant for Chlamydia trachomatis (P = .027). The odds ratio based on the 2 largest groups was significant with
AOR = 2.30 (1.33–3.97) for moderate discharge with scant discharge as the reference category.
* P < .05.
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…
direct or indirect measures of STI risk. A study evaluating
partnership status and condom use among women with TV
infections found that the most likely source of women’s expo-
sure to TV was their regular partners owing to the frequency
of sex and lack of condom use [17]. Future studies involving
TV infections in men are needed to substantiate this finding
and its clinical relevance.
Our finding that a proportion of men had persistent CT and
MG detected by NAATs at 4 weeks after recommended NGU
therapy is concerning. Determining whether the persistence of
these organism is due to reinfection or treatment failure is im-
portant, given that 13% of men diagnosed with chlamydia are
noted to have repeat infections [8]. Although we did not
monitor treatment of sexual partners in our study, we found no
significant associations between persistent CT or MG and risk
factors for possible reinfection including reported sex since the
last visit or frequency of condom use. Furthermore, only 2%
and 3% of male participants with CT and MG at baseline, re-
spectively, had negative results at visit 2 and positive results at
visit 3 consistent with reinfection. In comparison, 4% and 22%
of men with CT and MG at baseline, respectively, had persistent
detection at both visits 2 and 3, suggestive of treatment failure.
Persistent CT has already been noted in >5% of women
after azithromycin, raising the question of whether a longer
duration of treatment is needed, especially among those with
higher bacterial burdens [18, 19]. A few clinical isolates of CT
with mutations in the 23S ribosomal RNA gene associated
with resistance to macrolides have been reported [20];
however, antimicrobial resistance in CT has not been well in-
vestigated [21]. MG has also been reported to have high treat-
ment failures following both azithromycin and doxycycline
therapy [22, 23]. A study conducted among men with NGU
who were treated with doxycycline detected MG in 41% of
their participants with recurrent or persistent NGU [24].
Both persistent CT and MG in our study was associated
with the presence of a urethral discharge on examination and
elevated number of PMNs per HPF on the urethral Gram
stain at the follow-up visit. The presence of a visible discharge
and inflammatory cells may be indicative of an ongoing in-
flammatory process from a persistent infection or persistent
antigens or endotoxins from the initial infection. Whether the
ongoing inflammation noted in some men after NGU therapy
is due to a higher inoculum of CT/MG or the infecting
serovar (CT) is unknown, and warrants future study. The
cutoff point for separating men with urethritis from those
without urethritis has been established at 4 PMNs per HPF
[25], but the value of distinguishing between 5–15 vs >15
PMNs per HPF requires further consideration.
The possibility remains that persistent CT or MG after
NGU therapy may represent shedding of nonviable organisms
detected by NAATs, which is a plausible explanation for the
detection of CT, MG, and TV in some participants considered
to have achieved cure at 1 week after therapy (Figures 1 and
2). The time for CT clearance after azithromycin treatment
has been predicted to be between 16 and 18 days [26, 27];
however, the duration of NAAT positivity for MG after treat-
ment has not been reliably examined. We did not use cultures
to assess for viable organisms nor quantitative PCR to deter-
mine the copy number of organisms associated with persis-
tence after therapy. Therefore, further correlations between in
vitro studies and microbiological persistence of CT assessed by
culture and quantitative PCR would be important.
Limitations in our study that should be acknowledged
include our enrollment of participants from STI clinics that
are expected to have a higher prevalence of CT, MG, or TV
than other male populations. We did not investigate other or-
ganisms associated with NGU including U. urealyticum and
viruses, which could have been present in some of our partici-
pants who had none of the other pathogens detected. Our in-
clusion of only symptomatic men with possibly higher
organism burdens of CT, MG, or TV may have overestimated
the proportion of persistent infections, which may be lower in
asymptomatic men. We also defined persistent infections
based partly on a positive NAAT at 1 week after therapy if the
participant did not return thereafter, potentially resulting in
its overestimation since DNA from killed organisms may have
been detected in these cases. However, we identified only 3
such men in the CT group and 3 in the MG group.
Our results demonstrate that clinical failures among men
treated for NGU with recommended therapies are common
and that the majority are attributable to MG. Overall, persis-
tent detection of CT and MG via NAATs after treatment is
associated with clinical correlates of infection, although the
significance of persistent pathogens in men who are no longer
symptomatic is unknown. Unfortunately, the absence of com-
mercially available tests for MG detection precludes the diag-
nosis of MG infections in clinical practice. Considering that
MG had the highest prevalence relative to the other STIs at
baseline and that a high proportion of our male participants
had persistent MG after doxycycline, the preferred current
treatment regimen for NGU appears to be azithromycin
despite the possibility of CT treatment failures. Therefore,
future randomized clinical trials exploring the contribution of
other pathogens, potentially higher doses, or longer treatment
durations of azithromycin or other drug regimens (ie, moxi-
floxacin) are vital to determining the optimal therapy and
management of persistent NGU.
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